The various (many) guidelines were not designed with kidney disease in mind. Locally we have not used bisphosphonates very often in this group, tending to favour vitamin D preparations that are already in use. Two specific concerns are:
For patients with normal or mildly impaired kidney function, the Lothian Joint Formulary Committee recommendation for patients receiving ≥7.5mg prednisolone or equivalent is:
Risk factors for osteoporosis, or demonstration of osteoporosis will influence decisions. Note that bone density measurements are of unknown relevance in patients with renal failure, in whom osteodystrophy may confound interpretation.
COMMENCE PROPHYLAXIS WHEN STEROID TREATMENT IS INITIATED
|
Risk Factors |
|
Menopause <45 years |
|
Personal or family history of low-trauma fractures |
|
Amenorrhoea |
|
Slender build (BMI < 20kg/m2) |
|
Immobility |
Alternative Treatments
More information - Lothian Joint Formulary Guidance
Neil
Turner was the main author for this page, last amended
NOTE that the accuracy of any statements in this information CANNOT be guaranteed. It is published in the belief that it is correct, and we endeavour to keep it so - but we do make mistakes. Furthermore, over some subjects there are differing opinions, or differing degrees of certainty. We have usually not attempted to discuss these here because the aim has been to provide an immediate and brief guide. In all areas, prior medical knowledge is assumed. The EdRenHANDBOOK is not suitable for use by those without such a background. Contact us by email or at the address given at the foot of the contents page with any comments or corrections.